SCHEMBL2829908

SCHEMBL2829908

Brc1cccc2c1CCO2

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 1/20 0.42
ICAM1 P05362 1/20 0.42
ITGAL P20701 1/20 0.42
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 2/20 0.38
CRHBP P24387 2/20 0.38
CRHR2 Q13324 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
SLC9A1 P19634 5/20 0.37
MTNR1B P49286 8/20 0.36
KIF11 P52732 1/20 0.36
SLC9A5 Q14940 1/20 0.35
SLC9A2 Q9UBY0 1/20 0.35
PARP10 Q53GL7 1/20 0.35
PARP11 Q9NR21 1/20 0.35
MTNR1A P48039 6/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6584559 0.88 ITGB2 (0.39) ITGB2ICAM1ITGALLMNACRHBP
SCHEMBL31394887 0.88 ITGB2 (0.39) ITGB2ICAM1ITGALLMNACRHBP
SCHEMBL30231672 0.77 MTNR1B (0.40) ITGB2ICAM1ITGALMEN1KMT2A
SCHEMBL2830923 0.74 ITGB2 (0.42) ITGB2ICAM1ITGALMEN1KMT2A
SCHEMBL88337 0.74 ITGB2 (0.42) ITGB2ICAM1ITGALMEN1KMT2A
SCHEMBL31634086 0.74 ITGB2 (0.42) ITGB2ICAM1ITGALMEN1KMT2A
SCHEMBL964309 0.74 ITGB2 (0.42) ITGB2ICAM1ITGALMEN1KMT2A
SCHEMBL8081108 0.74 MAP3K14 (0.47) ITGB2ICAM1ITGALMEN1KMT2A
SCHEMBL5543467 0.74 ITGB2 (0.42) ITGB2ICAM1ITGALMEN1KMT2A
SCHEMBL945134 0.74 ITGB2 (0.42) ITGB2ICAM1ITGALMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113122061-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 CN claimed
US-20100298584-A1 PROCESS FOR PRODUCTION OF 4-VINYL-2,3-DIHYDROBENZOFURAN SUMITOMO CHEMICAL COMPANY LIMITED 2010-11-25 US claimed
EP-2236504-A1 PROCESS FOR PRODUCTION OF 4-VINYL-2,3-DIHYDROBENZOFURAN Sumitomo Chemical Company, Limited (JP) 2010-10-06 EP claimed
EP-4729516-A1 SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu NHWA Pharmaceutical Co., Ltd (CN) 2026-04-22 EP disclosed
WO-2025049746-A1 COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
WO-2024260319-A1 SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏恩华药业股份有限公司 2024-12-26 WO disclosed
WO-2024217519-A1 PYRROLE SULFONYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 天地恒一制药股份有限公司 2024-10-24 WO disclosed
US-20240083857-A1 2-Methyl-Quinazolines Bayer Pharma AG (DE) 2024-03-14 US disclosed
WO-2023150525-A1 COMPETITIVE AND NONCOMPETITIVE PIPERIDINE SULFONYL INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 VANDERBILT UNIVERSITY (US) 2023-08-10 WO disclosed
CN-109563063-B Method for preparing 4-substituted 2, 3-dihydro-1-benzofuran derivatives by cyclisation of 2- (2-diazonium-6-substituted phenyl) ethanoates 拜耳作物科学股份公司 2023-04-28 CN disclosed
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20150329566-A1 CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF DIVERCHIM (FR) 2015-11-19 US disclosed
US-20150329566-A1 CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF DIVERCHIM (FR) 2015-11-19 US disclosed
EP-2931708-A2 CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF Diverchim (FR) 2015-10-21 EP disclosed
WO-2014091167-A2 CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF DIVERCHIM (FR) 2014-06-19 WO disclosed
WO-2014091167-A2 CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF DIVERCHIM (FR) 2014-06-19 WO disclosed
CN-101925589-B Process for producing 4-vinyl-2, 3-dihydrobenzofuran SUMITOMO CHEMICAL CO 2013-03-27 CN disclosed
CN-101925589-A Process for producing 4-vinyl-2, 3-dihydrobenzofuran SUMITOMO CHEMICAL CO 2010-12-22 CN disclosed
US-20100298584-A1 PROCESS FOR PRODUCTION OF 4-VINYL-2,3-DIHYDROBENZOFURAN SUMITOMO CHEMICAL COMPANY LIMITED 2010-11-25 US disclosed
EP-2236504-A1 PROCESS FOR PRODUCTION OF 4-VINYL-2,3-DIHYDROBENZOFURAN Sumitomo Chemical Company, Limited (JP) 2010-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083857-A1 2-Methyl-Quinazolines NRAS, KRAS, KSR2 ITGB2 2427/4885ICAM1 4512/4885ITGAL 4203/4885
US-20150329566-A1 CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF HMBS, MMAB, FDPS ITGB2 3664/4885ICAM1 4315/4885ITGAL 4113/4885
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, USP19, USP39 ITGB2 4805/4885ICAM1 3473/4885ITGAL 4712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.